Endocrine Abstracts

Background: A recent, large phase III study (n=162) showed that treatment with pasireotide rapidly decreased urinary free cortisol (UFC) levels and improved signs and symptoms in patients with Cushing’s disease. Here, we report the experience of a patient enrolled in this trial who received pasireotide for 36 months.Results: A 31-year-old male presented in June 2008 with persistent Cushing’s disease despite two previous pituitary surgica...